CUSIP: 89422GAA5
Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Market price (% of par)
-
66.0%
-
Total 13F principal
-
$334,700,000
-
Principal change
-
+$41,075,833
-
Total reported market value
-
$220,380,890
-
Number of holders
-
20
-
Value change
-
+$27,118,701
-
Number of buys
-
7
-
Number of sells
-
6
Security key
89422GAA5
Report period
Q4 2023
Institutions
20
Top holders
10
Reporting periods
Holder history for CUSIP 89422GAA5
Recent filing periods:
Top shareholders of 89422GAA5 - TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q4 2023
As of 31 Dec 2023,
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by
20 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$334,700,000
in principal (par value) of the bond.
The largest 10 bondholders included
Context Capital Management, LLC, WOLVERINE ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., HIGHBRIDGE CAPITAL MANAGEMENT LLC, LAZARD ASSET MANAGEMENT LLC, UBS OCONNOR LLC, CITIGROUP INC, AVIVA PLC, CAPSTONE INVESTMENT ADVISORS, LLC, and BRAIDWELL LP.
This page lists
20
institutional bondholders reporting positions
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
Compare Q4 2023 vs Q3 2023 Across Filers
| Investor |
Q3 2023 Shares |
Q4 2023 Shares |
Share Diff |
Share Chg % |
Q3 2023 Value $ |
Q4 2023 Value $ |
Value Diff $ |
Value Chg % |
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.